

•					
	CERTIFICATE UNDER 37 C.F.R. 1.10 Docket No. 62605-11				
UTILITY	Express Mail Label No.: EL676470650US				
PATENT APPLICATION	Date of Deposit: December 17, 2001				
TRANSMITTAL	I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Commissioner for Patents, Box Patent Application, Washington, DC 29231				
(Only for new nonprovisional application under 37 CFR 1.53(b))	Geraldere Dei Signature				
APPLICATION ELEMENTS	ADDRESS TO/ Commissioner for Patents				
See MPEP chapter 600 concerning utility patent application contents.	Box Patent Application Washington, DC 20231				
Fee Transmittal Form     (Submit an original, and a duplicate for fee processing)     X Specification Total Pages 77     (preferred arrangement set forth below)	6. CD-Rom or CD-R, Large Table or Computer Program (Appendix)  7. Nucleotide and/or Amino Acid Sequence Submission				
- Descriptive Title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Sequence Listing or a Table Appendix	(if applicable, all necessary)  a. Computer Readable Form (CFR)  b. Paper copy (identical to computer copy)  c. Statement verifying identity of above copies				
- Reference to sequence listing of a Table Appendix  - Background of the Invention	ACCOMPANYING APPLICATION PARTS				
<ul> <li>Brief Summary of the Invention</li> <li>Brief Description of the Drawings (if filed)</li> <li>Detailed Description</li> </ul>	8. Assignment Papers (cover sheet & document(s))				
- Claim(s) - Abstract of the Disclosure	9. 37 CFR 3.73(b) Statement Power of Attorney				
3. 6 Drawing(s) (35 USC 113) Total Sheets 6	10. English Translation Document (if applicable)				
4. X Oath or Declaration/ Total Sheets 4  Power of Attorney  a. Newly executed (original or copy) b. X Copy from a prior application (37 CFR 1.63(d))  (for continuation/divisional with Box 16 completed) i. DELETION OF INVENTOR(S)  Signed statement attached deleting inventor(s) named in the prior application,	11. X Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations  12. X Preliminary Amendment  13. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)				
see 37 CFR 1.63(d)(2) and 1.33(b).	14. Request and Certification under 35 U.S.C. 122(b)(2)(B)(i)				
5. Application Data Sheet (See 37 CFR 1.76)	15. X Other: Citation of References				
16. If a CONTINUING APPLICATION, check appropriate box a an Application Data Sheet under 37 CFR 1.76:	and supply the requisite information below and in a preliminary amendment or in				
Continuation X Divisional Continuation-in	n-part (CIP) of prior application no: 08/951,873				
Prior Application Information: Examiner: J. Go	oldberg Group Art Unit: 1614				
For CONTINUATION OR DIVISIONAL APPS only: The entire disc supplied under Box 4b, is considered a part of the disclosure of the ac incorporated by reference. The incorporation can only be relied upon application parts.					
**	SPONDENCE ADDRESS				
X Customer Number or Bar Code Label	or X Correspondence address Below  Respectfully submitted				
Paul E. Dupont Sanofi-Synthelabo Inc. 9 Great Valley Parkway	46				

Malvern, PA 19355
Telephone No.: (610) 889-6338
Facsimile No.: (610) 889-8799

PATENT TRADEMARK OFFICE

Paul E. Dupont Reg. No. 27,438

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Division Under 37 C.F.R. 1.53(b) Application of: Lee et al.

Drive Application Social No. (

Prior Application Serial No.: 08/951,873

Prior Filing Date: October 17, 1997

Prior Group Art Unit: 1614

Anticipated Classification of this Application:

Class 514

Subclass 243.000

Examiner: J. Goldberg

For: 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE

CYTOTOXIC AGENTS

Commissioner for Patents Box Patent Application Washington, D.C. 20231

## **CERTIFICATE UNDER 37 C.F.R. 1.10**

Express Mail Label Number: EL676470650US

Date of Deposit: December 17, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee"Service on the date indicated above and is addressed to: Commissioner for Patents, Box Patent

Application, Washington, DC 20231

Geralfing Shee

## FEE TRANSMITTAL FORM

The filing fee for the above-identified has been calculated as shown below:

	Number Number		_	Rate	Basic Fee	
• •	Filed		Extra			\$740.00
Total Claims	26	-20 =	6	X	\$ 18.00 =	108.00
Independent Claims	4	- 3 =	1	X	\$ 84.00 =	84.00
Multiple dependent claims	s(s), if any				\$280.00 =	
Total Filing Fee:	<del></del>				,	\$932.00

X Please charge the following fees to Deposit Account No. 19-0091.

X Filing Fee of \$932.00 Assignment recordal fee of \$

Please charge any additional fees under 37 CFR 1.16 which may be required, or credit any overpayment, to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.

This application is being filed by "Express Mail" as of the date of this letter pursuant to 37 CFR 1.10(b).

Date: 12/17/01

Address:

Patent Department Sanofi-Synthelabo Inc. 9 Great Valley Parkway Malvern, PA 19355 Tele: (610) 889-8802 Fax: (610) 889-8799 Faul E. Dupont Reg. No. 27,438